Irsamla

Vortioxetine, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as an oral tablet for oral use. It acts on multiple serotonin receptors and inhibits serotonin reuptake, providing antidepressant effects for the treatment of major depressive disorder in adult patients.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets and providing reliable logistics for timely delivery.

Vortioxetine is used primarily in the management of depressive disorders.

Major depressive disorder: reduces depressive symptoms and improves functional outcomes.

Vortioxetine may cause a range of adverse reactions, from frequent mild events to rare serious conditions.

Common Side Effects: - Nausea - Headache - Dizziness - Constipation - Dry mouth - Insomnia

Serious or Rare Side Effects: - Serotonin syndrome - Suicidal thoughts or behavior - Severe hyponatremia - Allergic reactions (rash, angioedema) - QT interval prolongation - Severe skin reactions (Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should evaluate patient history and monitor for specific safety concerns. - Suicidal risk assessment: evaluate for emergent suicidal thoughts, especially at treatment start. - Serotonin syndrome: avoid concomitant serotonergic agents and educate patients on symptoms. - Hepatic impairment: use caution and consider dose adjustment. - Discontinuation: taper gradually to reduce withdrawal effects. - Drug interactions: review all concurrent medications for serotonergic activity. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Vortioxetine interacts with several drug classes; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs) - Linezolid - Tramadol - Other serotonergic antidepressants (e.g., SSRIs, SNRIs) - St. John’s wort

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., paroxetine) - CYP3A4 inhibitors (e.g., ketoconazole) - NSAIDs (increased bleeding risk) - Anticoagulants (enhanced anticoagulant effect) - Alcohol (potential additive CNS effects)